CD4 and hepatocellular carcinoma: Consistent with these results, the depletion of all these CD4+ T cell populations, including Th1, Th2, Th17, and Treg cells, through repeated intravenous injections of a neutralizing antibody against CD4 did not significantly affect the suppression of HCC by aldometanib (Supplementary information, Fig. S9k, l; see also validation data for the efficacy of CD4+ T cell clearance by the anti-CD4 neutralizing antibody in Supplementary information, Fig. S9m), suggesting that these CD4+ T cell populations do not play a major role in the aldometanib-induced suppression of HCC.